Vista Partners (“Vista”) has published updated coverage on four Dow 30 components 3M (MMM), Caterpillar (CAT), IBM (IBM) & UnitedHealth Group (UNH). The reports may be downloaded for FREE at the Vista Partners Coverage Section.

Vista recently published a report on Atossa Genetics (NasdaqCM: ATOS) a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions that announced additional findings from its Phase 1 study of Atossa’s proprietary oral Endoxifen recently.

About the authorJohn Heerdink

John is the Managing Director of Vista Partners LLC. Mr. Heerdink has advised public and private companies in the Technology, Life Sciences, Cleantech, Energy, Mining & Minerals and Consumer sectors. In addition, Mr. Heerdink has worked with companies seeking a listing on public exchanges via IPO, reverse merger and assisted foreign issuers seeking a listing on a U.S. exchange. Mr. Heerdink has assisted small-cap companies to raise debt and equity capital for growth, consummated mergers and acquisitions and performed all other matters dealing with investor relations and business development. He maintains an extensive relationship base in the investment community, lending industry and investment banking industry globally. He has founded, co-founded or launched/relaunched the following financial related institutions: Heerdink Advisory Services, LLC, Tribe Public LLC, United Capital Partners LLC & Vista Partners LLC. He has also held management positions: First Union Brokerage Services (Now Wells Fargo), Merriman Curhan Ford & Co., RAF Financial Services, & Bristol Myers Squibb. He is based in the San Francisco office. Mr. Heerdink has held the following Securities licenses: Series 24, 7, 79, 65, & 63. Mr. Heerdink earned a B.A. from the University of Southern Indiana and was an honors symposium graduate.

Join Vista Partners

I agree to the terms and conditions associated with downloading research, newsletters, and access to all content on this site. I have read and agree with all the terms and conditions in the disclaimer.